Redeye re-initiates coverage of Isofol Medical, a Swedish oncology biotech company targeting the multibillion-dollar colorectal cancer treatment market. With a renewed clinical strategy, strengthened financial backing, and strategic support from international partners, we see compelling upside potential as the company works to reestablish arfolitixorin as a next-generation treatment in metastatic colorectal cancer.
LÄS MER
